Form 4: Teladoc Health Executive Andrew Turitz Sells Shares Under 10b5-1 Trading Plan
SEC Form 4 Filing
EVP of Corporate Development at Teladoc Health, Andrew Turitz, sold 20,773 shares of common stock at $7.26 per share on September 4, 2024, under a pre-arranged 10b5-1 trading plan.
Summary
- On September 4, 2024, Andrew Turitz, the EVP of Corporate Development at Teladoc Health, sold 20,773 shares of the company's common stock.
- The sale was executed at a price of $7.26 per share.
- The transaction was conducted under a Rule 10b5-1 trading plan adopted by Turitz on June 4, 2024.
- Following the transaction, Turitz continues to directly own 20,773 shares of Teladoc Health.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing related to an executive's stock sale under a pre-arranged trading plan. It doesn't inherently convey positive or negative sentiment.
Industry Context
Executive stock sales are a common occurrence in publicly traded companies. The use of 10b5-1 trading plans allows insiders to sell shares at predetermined times and prices, avoiding accusations of trading on non-public information.
Stakeholder Impact
- The stock sale by an executive could have a minor impact on shareholder confidence.
Key Dates
| Date | Description |
|---|---|
| June 4, 2024 | Date the reporting person adopted the Rule 10b5-1 trading plan. |
| September 4, 2024 | Date of the transaction (sale of common stock). |
| September 5, 2024 | Date of the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.